Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced Bruker, a preeminent provider of high-performance scientific instruments and high-value analytical and diagnostic solutions, as a new Genedata Ready-to-Run partner. Bruker joins the rapidly growing list of technology providers who closely collaborate with Genedata to offer standardized integrations with the Genedata Biopharma Platform. Such integrations deliver automated end-to-end data processing – from raw data generation to result reporting and decision making – to streamline complex workflows, improve result quality, and reduce operational R&D costs. These capabilities, combined with the inherent scalability of the Genedata Biopharma Platform, maximize technology ROI and enable both partners to provide significant value add to their customers. Exemplary integrations with Bruker SPR-32 and rapifleX MALDI PharmaPulse (MPP) instruments will be featured at the SLAS 2019 8th Annual Conference and Exhibit at Bruker Booth #1051 and Genedata Booth #1317 (Walter E. Washington Convention Center).

Genedata and Bruker Join Forces to Support High Throughput Technologies
“To support the accelerated pace of drug discovery and development, we are continuously looking for ways to improve our customers’ R&D processes,” noted Dr. Rohan Thakur, Managing Director and Executive Vice President of Life Sciences at Bruker. “Many of our customers, who are among the world’s leading biopharmaceutical companies, rely on the Genedata Biopharma Platform for large scale data analysis. Therefore, giving our joint customers a standard integration between Bruker instruments and the Genedata Biopharma Platform eliminates time-consuming integrations and customizations. Moreover, our customers benefit from a new level of automation and streamlined workflows, which increase the speed of data analysis while improving overall results quality and R&D efficiency.”

Initial Bruker integrations include the Bruker SPR-32 and rapifleX MPP. Bruker SPR-32 enables high-throughput surface plasmon resonance (SPR) analysis of molecular interaction. Sensorgrams are automatically imported into the Genedata Biopharma Platform via the Ready-to-Run integration and converted to affinity results. Bruker rapifleX MPP is a MALDI TOF/TOF instrument for a full-deck screen with millions of compounds, providing detailed mass spectrometry read-outs, which are automatically imported and analyzed in the Genedata Biopharma Platform. Additional integrations, driven by customer request, are planned for the future with Genedata Screener® and Genedata Expressionist®, both of which are part of the Genedata Biopharma Platform.

Ready-to-Run integrations provide the fastest and most efficient way to connect instruments to the Genedata Biopharma Platform – processing raw data to quality results in just minutes. Currently, Ready-to-Run supports screening technologies such as high-content, flow cytometry, biophysical and ion channel screening as well as mass spectrometry, acoustic liquid handling, and multi-parallel bioreactors. Integrations significantly automate high-throughput screening workflows for large-scale experiments, giving researchers the ability to screen huge chemical libraries against a range of targets for lead discovery. Effortlessly handling campaigns of any size with millions of compounds, the Bruker/Genedata integrations will give customers access to the latest screening technologies at the highest throughput.

“We partner with innovative technology leaders that share our vision to streamline complex experimental processes and lower the ever-rising costs of biopharmaceutical R&D. Therefore, we are delighted to welcome Bruker as our latest Ready-to-Run partner,” said Dr. Othmar Pfannes, CEO of Genedata. “Ready-to-Run not only gives partners like Bruker and us a simple way to help our joint customers automate complex data workflows, but the very nature of the program also eliminates the time and costs associated with integration services and projects, which effectively reduces a customer’s total cost of ownership.”

About Genedata Ready-to-Run
The vendor-agnostic Genedata Biopharma Platform maintains flexible data import APIs, enabling integration with virtually any instrument. Many devices, however, produce highly complex data with massive amounts of data per plate. The Genedata Ready-to-Run program addresses these data acquisition challenges. With the oversight and support of respective instrument companies, Ready-to-Run integrations are instrument-specific, versioned, tested, and maintained by Genedata as part of its standard licensing agreements. The Ready-to-Run program is open to all qualified vendors. Instrument providers interested in joining the program may submit their requests to ready-to-run@genedata.com.

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.

www.genedata.com
Follow Genedata on LinkedIn

Disclaimer
The statements in this press release that relate to future plans, events, or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.